ANZCTR search results

This study is a prospective, randomised clinical study comparing clinical outcomes of Knee Replacement using the Oxford Knee Score (OKS), in patients receiving either Bicompartmental Knee Replacement performed using Stryker’s robotic-arm assisted surgery system Mako, to Total Knee Replacement using the Triathlon Total Knee System performed with either conventional instrumentation or navigation. Functional and radiographic outcomes will be additionally collected as part of this study. The study will be conducted in patients with non-inflammatory degenerative joint disease who are randomised to either the Restoris'Registered TradeMark' MCK Multicompartmental Knee System for Bicompartmental Knee Replacement (BKR), or the Triathlon Total Knee System for Total Knee Replacement (TKR), with a minimum 2 year patient evaluation period.

This study aims to evaluate the efficacy of nutrition therapy with additional high intensity interval training in improving cancer-related fatigue and quality of life in men with prostate cancer on androgen deprivation therapy. Who is it for? Men aged 18 years or over who have prostate cancer and are currently being treated with androgen deprivation therapy (ADT), for longer than 3 months. Study details Research has found that men with prostate cancer treated with ADT have a high prevalence of cancer-related fatigue, which affects quality of life during and after treatment. Whilst the benefits of both dietary modification and exercise prescription have been well described in prostate cancer prevention and progression, little is known about the influence of nutrition therapy and high intensity exercise on cancer-related fatigue in men with prostate cancer during or after ADT treatment. This study aims to evaluate the efficacy of nutrition therapy and high intensity exercise in prostate cancer-related fatigue. All participants in this study are randomly allocated (by chance) to one of the two groups. Participants in one group will be invited to attend fortnightly 45 min long dietetic consults with an Accredited Practicing Dietitian for 20 weeks and to undertake high intensity interval training sessions, 3 times per week, in weeks 12-20. Participants in the second group will receive usual care monitoring followed by moderate or high intensity interval training, 3 times per week, for eight weeks after usual care has finished. The usual care group will continue to be treated with ADT, or adjunctive ADT with chemotherapy/radiotherapy for the study duration. Throughout the study, participants will be asked to answer questionnaires on prostate cancer-related fatigue and quality of life as well as have blood samples taken and perform some physical function tests. It is hoped that this study will help assist in alleviating cancer-related fatigue, and improving quality of life for men with prostate cancer treated with ADT.

This study will assess consecutively the safety, tolerability, and pharmacokinetics of single and multiple doses of CTP-730 in healthy volunteers.

Military personnel returning from overseas deployment often suffer from sleep difficulties. Demanding and altered working hours, challenging environmental conditions, high work tempo, and altered interpersonal and support environments contribute to disturbed sleep during operations. If left untreated, sleep difficulties can lead to poorer mental health outcomes; in fact, sleep complications may become a chronic health issue. The research will evaluate the effectiveness of two treatments. Cognitive Behavioural Therapy for Insomnia (CBT-i) and Bright Light Therapy (BLT) for improving sleep and mental health will be trialed in a sample of 40 ADF personnel.

Dementia is the single greatest cause of disability in older Australians and the third leading cause of disability burden in Australia. Due to our aging population the number of Australians living with dementia is expected to increase rapidly over the next decade placing additional burden on the health system and on the unpaid/family carers of people with dementia. Behavioural changes occur in 90% of people with dementia. These changes are stressful and challenging for carers. The purpose of this study is to examine an online educational training program that teaches carers of people with dementia ways to manage common behaviours. It is expected that the program will reduce carer burden and stress.

This is a double-blind, randomised, placebo-controlled study to evaluate the efficacy of a herbal formulation. The aim is to investigate if the formulation reduces the severity and duration of cold & flu symptoms compared to placebo.

This pilot study will determine the feasibility of a second line combination chemotherapy of NAB-Paclitaxel and capecitabine for the treatment of advance biliary cancer. Who is it for? You may be eligible to join this study if you are aged 18 years or above, have histologically proven unresectable biliary tract cancer and have had prior chemotherapy treatment with gemcitabine/platinum. Study Details: All participants will receive combination chemotherapy using NAB-Paclitaxel and Capecitabine for as long as their disease responds to treatment and will be followed up every 12 weeks (until death) after end of treatment with CT imaging, status and quality of life assessments in order to determine feasibility, clinical benefit, survival rates and impact of treatment on quality of life.

Loss of motor function and shoulder pain are known outcomes of stroke that affect patients’ well being and independence. Physiotherapy routinely uses a variety of approaches to address these issues, including facilitating improved motor activation and better shoulder alignment. Using rigid strapping tape has been shown to have some benefits as an adjunct to treatment however, more recently kinesiology tape which is more flexible has become readily available. This has been used on many patient and athletic groups, but has only been used once in a group with stroke, and this was not at the shoulder. This study aims to determine if kinesiology tape is useful as part of a treatment approach to managing the affected shoulder in acute stroke. Participants will be recruited from admissions to ward G51 at Sir Charles Gairdner Hospital over a period of 4 months. The study will be a single blinded, randomised controlled trial with the control group receiving placebo taping and the intervention group will receive therapeutic taping. Pain, shoulder position, muscle stiffness and range of movement will be recorded every 3 days during the trial to determine how these factors change over time. Measures of motor impairment in the arm will be taken on admission and discharge (or at 14 days, whichever comes first). It is expected that there will be no adverse effects of the taping. It is anticipated there may be some benefit in using the kinesiology tape for shoulder pain and motor activation, however this problem is multifactorial and the effect size is expected to be low. This study is a pilot study to test the protocol and determine effect size with a view to a more extensive study in the future.

The Ripple project concerns young people who are removed from their families of origin because of significant risk of harm and placed in State care. These young people often have multiple and complex needs, poor mental health, high risk of mental disorders and poor social outcomes. The overall aim of the project is to assess whether a mental health intervention that enhances the care roles and capacities of carers in Out of Home Care (OoHC) will improve (i) the consistency and quality of OoHC for all young people (12-17 years) in the OoHC sector, and (ii) access to early intervention when indicated for prevention and treatment of mental illness. Both aims will contribute to improving the mental health of young people living in OoHC.

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease study (the “A4 study”) is a clinical trial testing an anti-amyloid investigational drug (called solanezumab, also known as LY2062340) in older individuals who have evidence of elevated amyloid build-up in their brains, but who do not yet show symptoms of AD. The primary purpose of this study is to test whether solanezumab can slow possible AD-related damage in the brain and to delay progression of AD-related memory loss associated with brain amyloid.